ClinicalTrials.gg
Active, not recruitingNCT06268886TargetTau-1Updated Nov 2, 2026

Study to Evaluate the Efficacy, Safety, and Tolerability of an Anti-MTBR Tau Monoclonal Antibody (BMS-986446) in Participants With Early Alzheimer's Disease

A Phase 2 interventional study of BMS-986446 and Placebo in Alzheimer Disease, Early Onset, sponsored by Bristol-Myers Squibb. Active, not recruiting at 176 sites in 10 countries. Open to participants aged 50 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by Bristol-Myers Squibb · Phase 2, Interventional, and Treatment

Updated Nov 2, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
310
Allocation
Randomized
Ages
50 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 26 studies in Alzheimer Disease by Bristol-Myers Squibb — 12 open to participants now, 13 under way, 10 of them phase 3. Alzheimer Disease · Bristol-Myers Squibb.

Planned enrollment
11th of 26
310 · median 165
Started
2024
with 1 other
Phase 2
4 of 26
1 open now
Primary completion
2026-12
later than 2 of 12 live
Registered
17th of 26
by date

Among the 26 studies in Alzheimer Disease by Bristol-Myers Squibb, this one is the 11th largest by planned enrollment, is one of 2 that started in 2024, is one of 4 in phase 2, reaches primary completion later than 2 of the 12 other live ones, and was the 17th registered.

Alzheimer Disease

3,970 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

12 of the 26 studies in Alzheimer Disease by Bristol-Myers Squibb are open now, in 12 countries. Recruiting first, the newest first:

7 more — sign in →

By country, each count listing its studies:

All 12 open studies →

Who these studies take

Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.

This study: 50 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies in Alzheimer Disease by Bristol-Myers Squibb, or all of them as a file.
02

Study summary

The purpose of this study is to assess the effectiveness, safety, and tolerability of BMS-986446 an Anti-MTBR Tau Monoclonal Antibody in participants with Early Alzheimer's Disease.

03

Conditions studied

  • Alzheimer Disease, Early Onset

Keywords

  • Alzheimer Disease
  • BMS-986446
  • Neurodegenerative disease
  • Dementia
  • Brain Diseases
  • Anti-MTBR tau monoclonal antibody
  • TargetTau-1
  • Anti-tau therapy
04

Who can participate

Ages eligible
50 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Mild cognitive impairment (MCI) due to Alzheimer's disease (AD) or mild AD dementia consistent with the National Institute on Aging and the Alzheimer's Association (NIA-AA) core clinical criteria.
  • Global Clinical Dementia Rating (CDR) score of 0.5 to 1.0 and a CDR-Memory Box score of 0.5 and greater at screening and Baseline.
  • Evidence of AD pathology.
  • Objective impairment in episodic memory as indicated by at least 1 standard deviation below age-adjusted mean in the Wechsler Memory Scale IV-Logical Memory Subtest II (WMS-IV LM II).
  • Mini Mental Status Examination () score ≥ 20 to 28 (inclusive).

Exclusion criteria

Exclusion Criteria

  • Any evidence of a condition that may affect cognition other than AD.
  • to PET imaging.
  • Inability to tolerate or contraindication to magnetic resonance imaging.
  • Any serious medical condition that could, in the opinion of the investigator, affect the participant's safety or interfere with study assessments.
  • Geriatric Depression Scale (GDS) score greater than or equal to 8 at screening.
  • Other protocol-defined Inclusion/Exclusion criteria apply.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
310 participants (estimated)

Study arms

  • Placebo comparator
    Placebo

    Other: Placebo

  • Experimental
    BMS-986446 Dose A

    Drug: BMS-986446

  • Experimental
    BMS-986446 Dose B

    Drug: BMS-986446

Interventions

  • Specified dose on specified days

  • OtherPlacebo

    Specified dose on specified days

06

What researchers measure

Primary outcomes

  1. Change from baseline in brain tau deposition as measured by tau positron emission tomography (PET)

    Time frame: At week 76

Secondary outcomes

  1. Change from baseline in Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) score

    Time frame: At week 76

  2. Change from baseline in Mini Mental State Examination (MMSE) score

    Time frame: At week 76

  3. Change from baseline in integrated Alzheimer's Disease Rating Scale (iADRS) score

    Time frame: At week 76

  4. Change from baseline in Alzheimer's Disease Assessment Scale-Cognitive subscale (ADASCog14) score

    Time frame: At week 76

  5. Change from baseline in Alzheimer's Disease Cooperative Study-instrumental Activities of Daily Living scale (ADCS-iADL) score

    Time frame: At week 76

07

Study locations

176 sites
  • Local Institution - 0068
    Chandler, Arizona 85226-3732, United States
  • Local Institution - 0102
    Gilbert, Arizona 85297-0441, United States
  • Local Institution - 0019
    Phoenix, Arizona 85004, United States
  • Local Institution - 0018
    Scottsdale, Arizona 85253, United States
  • Local Institution - 0026
    Scottsdale, Arizona 85258-4595, United States
  • Local Institution - 0077
    Tucson, Arizona 85718-6522, United States
  • Local Institution - 0038
    Tucson, Arizona 85718-6632, United States
  • Local Institution - 0164
    Encino, California 91316-1511, United States
  • Local Institution - 0139
    Fullerton, California 92835-1040, United States
  • Local Institution - 0191
    Irvine, California 92614-9403, United States
  • Local Institution - 0234
    Long Beach, California 90804-2128, United States
  • Local Institution - 0142
    Los Alamitos, California 90720-3589, United States
  • Local Institution - 0037
    Napa, California 94558-2415, United States
  • Local Institution - 0209
    Sacramento, California 95816, United States
  • Local Institution - 0052
    San Francisco, California 94143-2350, United States
  • Local Institution - 0137
    Santa Ana, California 92705-8675, United States
  • Local Institution - 0046
    Sherman Oaks, California 91403-2131, United States
  • Local Institution - 0106
    Danbury, Connecticut 06810-4088, United States
  • Local Institution - 0148
    New Haven, Connecticut 06510, United States
  • Local Institution - 0056
    New Haven, Connecticut 06511-5249, United States
  • Local Institution - 0153
    Stamford, Connecticut 06905-1206, United States
  • Local Institution - 0022
    Altamonte Springs, Florida 32714-2436, United States
  • Local Institution - 0048
    Atlantis, Florida 33462-6631, United States
  • Local Institution - 0228
    Boca Raton, Florida 33428-2236, United States
  • Local Institution - 0250
    Boca Raton, Florida 33487-3626, United States
  • Local Institution - 0224
    Bradenton, Florida 34205, United States
  • Local Institution - 0020
    Clermont, Florida 34711-5933, United States
  • Local Institution - 0009
    Daytona Beach, Florida 32117-5532, United States
  • Local Institution - 0213
    Fort Myers, Florida 33912-4302, United States
  • Local Institution - 0059
    Greenacres City, Florida 33467, United States
  • Local Institution - 0207
    Hialeah, Florida 33012-4170, United States
  • Local Institution - 0212
    Hialeah, Florida 33015-5110, United States
  • Local Institution - 0198
    Hialeah, Florida 33016-1814, United States
  • Local Institution - 0151
    Lady Lake, Florida 32159, United States
  • Local Institution - 0146
    Lakeland, Florida 33805-2208, United States
  • Local Institution - 0192
    Maitland, Florida 32751-3320, United States
  • Local Institution - 0143
    Maitland, Florida 32751, United States
  • Local Institution - 0027
    Merritt Island, Florida 32952-3616, United States
  • Local Institution - 0203
    Miami, Florida 33032, United States
  • Local Institution - 0058
    Miami, Florida 33122-1335, United States
  • Local Institution - 0034
    Miami, Florida 33125-4719, United States
  • Local Institution - 0211
    Miami, Florida 33126, United States
  • Local Institution - 0195
    Miami, Florida 33133-4231, United States
  • Local Institution - 0014
    Miami, Florida 33135-2957, United States
  • Local Institution - 0005
    Miami, Florida 33135-2968, United States
  • Local Institution - 0208
    Miami, Florida 33135-4759, United States
  • Local Institution - 0013
    Miami, Florida 33135, United States
  • Local Institution - 0008
    Miami, Florida 33137-2706, United States
  • Local Institution - 0199
    Miami, Florida 33144, United States
  • Local Institution - 0206
    Miami, Florida 33155-4630, United States
  • Local Institution - 0176
    Miami, Florida 33155-6540, United States
  • Local Institution - 0071
    Miami, Florida 33166-2710, United States
  • Local Institution - 0156
    Miami, Florida 33175-3598, United States
  • Local Institution - 0249
    Miami, Florida 33176-2151, United States
  • Local Institution - 0039
    Miami, Florida 33176-7947, United States
  • Local Institution - 0225
    Miami, Florida 33176, United States
  • Local Institution - 0197
    Miami Springs, Florida 33166-7225, United States
  • Local Institution - 0217
    Naples, Florida 34105, United States
  • Local Institution - 0017
    New Port Richey, Florida 34652-4020, United States
  • Local Institution - 0144
    Ocala, Florida 34471, United States
  • Local Institution - 0202
    Orlando, Florida 32806-8521, United States
  • Local Institution - 0219
    Orlando, Florida 32807, United States
  • Local Institution - 0035
    Orlando, Florida 32819-8031, United States
  • Local Institution - 0238
    Orlando, Florida 32832, United States
  • Local Institution - 0210
    Port Orange, Florida 32127-5170, United States
  • Local Institution - 0204
    Sarasota, Florida 34239-3228, United States
  • Local Institution - 0012
    Stuart, Florida 34997-5765, United States
  • Local Institution - 0136
    Stuart, Florida 34997-6405, United States
  • Local Institution - 0200
    Tampa, Florida 33607-6210, United States
  • Local Institution - 0080
    Tampa, Florida 33607-6616, United States
  • Local Institution - 0087
    Tampa, Florida 33609-4049, United States
  • Local Institution - 0042
    Tampa, Florida 33613-4808, United States
  • Local Institution - 0194
    Viera, Florida 32940-7948, United States
  • Local Institution - 0011
    Wellington, Florida 33414-9320, United States
  • Local Institution - 0223
    West Palm Beach, Florida 33407-3234, United States
  • Local Institution - 0149
    West Palm Beach, Florida 33409-6611, United States
  • Local Institution - 0029
    Windermere, Florida 34786-8919, United States
  • Local Institution - 0101
    Winter Park, Florida 32789-1848, United States
  • Local Institution - 0154
    Winter Park, Florida 32792, United States
  • Local Institution - 0105
    Columbus, Georgia 31909-1692, United States
  • Local Institution - 0236
    Chicago, Illinois 60611-2818, United States
  • Local Institution - 0021
    Chicago, Illinois 60640-2831, United States
  • Local Institution - 0161
    Elk Grove Village, Illinois 60007-3362, United States
  • Local Institution - 0003
    Gurnee, Illinois 60031, United States
  • Local Institution - 0145
    Park Ridge, Illinois 60068, United States
  • Local Institution - 0081
    Springfield, Illinois 62702-4968, United States
  • Local Institution - 0235
    Boston, Massachusetts 02116, United States
  • Local Institution - 0025
    Boston, Massachusetts 02131-2515, United States
  • Local Institution - 0015
    Braintree, Massachusetts 02184, United States
  • Local Institution - 0174
    Foxborough, Massachusetts 02035-1309, United States
  • Local Institution - 0118
    Methuen, Massachusetts 01844-5864, United States
  • Local Institution - 0040
    Newton, Massachusetts 02459-3328, United States
  • Local Institution - 0120
    Plymouth, Massachusetts 02360-7223, United States
  • Local Institution - 0045
    Watertown, Massachusetts 02472-4153, United States
  • Local Institution - 0119
    Portsmouth, New Hampshire 03801-6822, United States
  • Local Institution - 0031
    Princeton, New Jersey 08540-2859, United States
  • Local Institution - 0062
    Toms River, New Jersey 08755-5043, United States
  • Local Institution - 0060
    Albany, New York 12208-3464, United States
  • Local Institution - 0157
    Amherst, New York 14226-1727, United States
  • Local Institution - 0061
    Manhasset, New York 11030-3816, United States

Showing the first 100 of 176 sites across 10 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See Plan Description

Access criteria: See Plan Description

Data sharing details ↗ · www.bms.com

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2024 (actual). Primary completion is estimated for Dec 2026, 32 months after the start.

Of 131 industry-sponsored phase 2 interventional studies under Alzheimer Disease, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 39. This study's planned 32 months is above that.

Counting every sponsor, half of 258 studies reached it within 37 months; a quarter within 21 and three quarters within 58.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 2, 2026: primary completion Mar 2027 → Dec 2026 and completion Mar 2027 → Apr 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 13, 2024
First posted
Feb 20, 2024
StartActual
Mar 20, 2024
Primary completionEst.
Dec 17, 2026was Mar 2027
CompletionEst.
Apr 17, 2028was Mar 2027
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Mar 18, 2027→Dec 17, 2026
Nov 2, 2026
Study completion
Mar 18, 2027→Apr 17, 2028
Nov 2, 2026
Show all 1 update
  1. Nov 2, 2026
    Primary completion Mar 18, 2027→Dec 17, 2026
    Study completion Mar 18, 2027→Apr 17, 2028
    + 3 other changes: identifiers, verification date and data sharing statement

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06268886
Responsible party
Sponsor
First posted
Feb 20, 2024
Start date
Mar 20, 2024
Primary completion
Dec 17, 2026 (estimated)
Completion
Apr 17, 2028 (estimated)
Last update
Nov 2, 2026

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Moponetug

Start the discussion